Skip to main content
  • INVEST IN OUR FUTURE
  • INVEST IN OUR FUTURE
  • INVEST IN OUR FUTURE

A targeted investment strategy

Xerys is a portfolio management company specialising in private equity with an approach that makes the entrepreneur’s vision central to its investment philosophy. It aims to support the managers of Xerys Funds portfolio companies at all stages of their growth, from venture capital to maturity.

JACQUES SIMONNET

JACQUES SIMONNET

Chairman of the supervisory board and founder

OLIVIER OSSIPOFF

OLIVIER OSSIPOFF

Chairman

OUR PHILOSOPHY

The Xerys approach

« The creation of Xerys aims to meet the need to reconcile two major issues for business growth. On the one hand, entrepreneurs who wish to successfully carry out their growth ambitions need tailored, financial guidance but also strategic and operational support. On the other hand, investors are looking for transparency and control of their investments.…


OUR STRATEGY

AN ORIGINAL APPROACH TO A CAPITAL INVESTOR

100%

INDEPENDENT


15-90M€

INVESTMENT
TICKET


6

COMPANIES
IN PORTFOLIO

2014

Approval of the Authority
Financial Markets

Strong expertise

The governance of Xerys Invest is structured around a supervisory board and a directory with complementary experiences

Strong involvement

The management team and the experts are involved in the monitoring of the participations

Convergent interests

The management team is systematically interested in the performance of investments

Xerys therefore immediately establishes a constructive and proactive proximity relationship with the managers of its investments to assist and advise them in their strategic decision-making, arbitration and value creation.
With this original approach, Xerys establishes a relationship of trust with managers and investors, fostering a creation of shared value over the medium term.

3 SECTORS OF INVESTMENT


Santé


Sustainable
development


Connected
Technologies

NEWS

Alzprotect

ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT

Alzprotect, a biopharmaceutical company based in Lille, is currently testing an innovative drug against a neurodegenerative disease closely related to ...
Biolog-id

Biolog-id is awarded a multi-year contract with CHMT hospital center for an end-to-end Transfusion solution.

After a successful 6-months pilot project, CHMT decides to adopt all modules of the Biolog Transfusion solution: Encoding, Processing, Transport, ...
Biolog-id

An executive visit of the Global Diwan to learn about the utilisation of Biolog-id’s Transfusion Solution in Kuwait

Paris, France (February 1st, 2023) – Kuwait Blood Transfusion Administration Services (BTAS) is implementing the advanced transfusion solution for blood ...

OUR PARTICIPATIONS

XERYS FRANCE

73 boulevard haussmann

75008 Paris - France

+33 (0)1 82 52 12 25

FOLLOW-US: